J&J discontinues mid-stage dengue study, citing deprioritization of communicable disease work
What’s left of Johnson & Johnson’s infectious disease work continues to shrink, after the company announced Friday that it had stopped work on a mid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
